Panel Backs Limited New Olaparib Use in Prostate Cancer
An expert panel recommended restricting the expanded first-line indication to patients whose metastatic castration-resistant prostate tumors have BRCA mutations.
Medscape Medical News
source https://www.medscape.com/viewarticle/991408?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/991408?src=rss
Comments
Post a Comment